LUMARK

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, Poland

Active ingredients

The drug LUMARK contains one active pharmaceutical ingredient (API):

1 Lutetium ¹⁷⁷Lu oxodotreotide UNII BRH40Y9V1Q - LUTETIUM LU-177

Lutetium (177Lu) oxodotreotide has a high affinity for subtype 2 somatostatin receptors (sst2). It binds to malignant cells which overexpress sst2 receptors. Lutetium-177 (177Lu) is a βemitting radionuclide with a maximum penetration range in tissue of 2.2 mm (mean penetration range of 0.67 mm), which is sufficient to kill targeted tumour cells with a limited effect on neighbouring normal cells. Read about Lutetium ¹⁷⁷Lu oxodotreotide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V10XX04		V Various → V10 Therapeutic radiopharmaceuticals → V10X Other therapeutic radiopharmaceuticals → V10XX Various therapeutic radiopharmaceuticals
Discover more medicines within V10XX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1691737
Country: IT	Agenzia del Farmaco	Identifier(s): 044290017
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1077354
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100351593